Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

This study is testing a drug called tarlatamab — an immunotherapy that helps the immune system attack cancer cells — in people with an aggressive, rare form of cancer called extra-pulmonary neuroendocrine carcinoma (a neuroendocrine cancer that starts outside the lungs) whose cancer has returned or has not responded to previous treatment. **You may be eligible if...** - You are 19 or older - You have been confirmed by biopsy to have relapsed or treatment-resistant extra-pulmonary neuroendocrine carcinoma (cancers such as small cell or large cell neuroendocrine carcinoma originating from the gut, pancreas, prostate, or other sites) - You have received prior treatment that did not work **You may NOT be eligible if...** - Your cancer originated in the lungs (this trial is specifically for cancers outside the lungs) - You have not yet tried other standard treatments - You have health conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.